다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Biomedical science letters = 대한의생명과학회지, v.30 no.2, 2024년, pp.37 - 48
Si-Yeon Ryu (Department of Biomedical Laboratory Science, Konyang University) , Se-Yun Hong (Department of Biomedical Laboratory Science, Konyang University) , Keun-Sik Kim (Department of Biomedical Laboratory Science, Konyang University)
AI-Helper
Liposomes are one of the most actively studied and promising drug delivery systems for the treatment of various diseases. In this study, an aptamer-conjugated liposome called "aptamosome" was used, in which an anti-PD-L1 aptamer targeting cancer cells was conjugated to the liposome. These aptamosome...
Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune？checkpoint inhibitors; a systematic review and meta-analysis.？Clin Oncol (R. Coll. Radiol). 2016. 28: 127.
Agnello L, Camorani S, Fedele M, Cerchia L. Aptamers and？antibodies: Rivals or allies in cancer targeted therapy? Explor？Target Antitumor Ther. 2021. 2: 107-121.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome:？Classification, preparation, and applications. Nanoscale Res？Lett. 2013. 8: 102-102.
Alshaer W, Hillaireau H, Vergnaud J, et al. Aptamer-guided？siRNA-loaded nanomedicines for systemic gene silencing in？CD-44 expressing murine triple-negative breast cancer model.？J Control Release. 2018. 271: 98-106.
Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angewandte Chemie International Edition. 2006. 45: 8149-8152.
Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse？events for anti-PD-1 and anti-PD-L1 drugs: Systematic review？and meta-analysis. BMJ. 2018. 360: k793.
Chen S, Dominik PK, Stanfield J, et al. Dual checkpoint blockade？of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer. 2021. 9: e003464. doi: 10.1136/jitc-003464.
Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic？regulators for cancer immunotherapy. Int J Biochem Cell Biol. 2018. 98: 65-74.
Ganson NJ, Povsic TJ, Sullenger BA, et al. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic？reactions to pegnivacogin, a PEGylated RNA aptamer. J？Allergy Clin Immunol. 2016. 137: 1610-1613.e7.
Gao T, Mao Z, Li W, Pei R. Anti-PD-L1 DNA aptamer antagonizes？the interaction of PD-1/PD-L1 with antitumor effect. J Mater？Chem B. 2021. 9: 746-756.
Gilboa E, Berezhnoy A, Schrand B. Reducing toxicity of immune？therapy using aptamer-targeted drug delivery. Cancer Immunol？Res. 2015. 3: 1195-1200.
Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action？and rationale for the use of checkpoint inhibitors in cancer.？ESMO Open. 2017. 2: e000213-000213. eCollection 2017.
Jain A, Maheshwari V, Alam K, Mehdi G, Sharma SC. Apoptosis？in premalignant and malignant squamous cell lesions of？the oral cavity: A light microscopic study. Indian J Pathol？Microbiol. 2009. 52: 164-166.
Kennedy LB, Salama AKS. A review of cancer immunotherapy？toxicity. CA Cancer J Clin. 2020. 70: 86-104.
Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome？for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022. 348: 893-910.
Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome？composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021.？176: 113851.
Le VKH, Pham TPD, Truong DH. Delivery systems for vorinostat？in cancer treatment: An updated review. Journal of Drug？Delivery Science and Technology. 2021. 61: 102334.
Li T, Yao F, An Y, Li X, Duan J, Yang X. Novel complex of PD-L1 aptamer and holliday junction enhances antitumor efficacy？in vivo. Molecules. 2021. 26: 1067. doi: 10.3390/molecules26041067.
Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer？immunotherapy: A comprehensive review and perspective of？the 2018 china cancer immunotherapy workshop in beijing. J.？Hematol Oncol. 2018. 11: 142-143.
Liu B, Zhang J, Liao J, et al. Aptamer-functionalized nanoparticles？for drug delivery. J Biomed Nanotechnol. 2014. 10: 3189-3203.
Lv H, Wang T, Ma F, et al. Aptamer-functionalized targeted siRNA？delivery system for tumor immunotherapy. Biomed Mater. 2022. 17: 10.1088/1748-605X/ac5415.
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA？approval summary: Vorinostat for treatment of advanced？primary cutaneous T-cell lymphoma. Oncologist. 2007. 12:？1247-1252.
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019. 16: 563-580.
Melosky B, Juergens R, McLeod D, et al. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer. 2019. 134: 259-267.
Nayak A, Raikar A, Kotrashetti V, Nayak R, Shree S, Kambali S.？Histochemical detection and comparison of apoptotic cells in？the gingival epithelium using hematoxylin and eosin and？methyl green-pyronin: A pilot study. J Indian Soc Periodontol. 2016. 20: 294-298.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R.？Nanocarriers as an emerging platform for cancer therapy.？Nano-Enabled Medical Applications. 2020. 61-91.
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies？for cancer immunotherapy. Nat Rev Drug Discov. 2019. 18:？175-196.
Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell. 2018.？175: 313-326.
Terranova-Barberio M, Thomas S, Ali N, et al. HDAC inhibition？potentiates immunotherapy in triple negative breast cancer.？Oncotarget. 2017. 8: 114156-114172.
West AC, Johnstone RW. New and emerging HDAC inhibitors for？cancer treatment. J Clin Invest. 2014. 124: 30-39.
Xu W, Siddiqui IA, Nihal M, et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy？of prostate cancer. Biomaterials. 2013. 34: 5244-5253.
Zheng H, Zhao W, Yan C, et al. HDAC inhibitors enhance T-cell？chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2016.？22: 4119-4132.
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.